Annual Drug Patent Expirations for EVOCLIN
Evoclin is a drug marketed by Mylan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for EVOCLIN.
This drug has thirty patent family members in fifteen countries.
The generic ingredient in EVOCLIN is clindamycin phosphate. Additional details are available on the clindamycin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
